RIPK1 promotes inflammation and β-amyloid accumulation in Alzheimer's disease.

Rubinsztein, David

View / Open Files

Accepted version (PDF, 514Kb)

Authors

Rubinsztein, David

Publication Date

2017-10-10

Journal Title

Proc Natl Acad Sci U S A

ISSN

0027-8424

Publisher

Proceedings of the National Academy of Sciences

Volume

114

Issue

Pages

10813-10814

Language

eng

Type

Article

This Version

Physical Medium

Print-Electronic

Metadata

Show full item record

Citation

Rubinsztein, D. (2017). RIPK1 promotes inflammation and β-amyloid accumulation in Alzheimer's disease.. Proc Natl Acad Sci U S A, 114 (41), 10813-10814. https://doi.org/10.1073/pnas.1715241114

Abstract

Alzheimer’s disease (AD), the leading cause of dementia, is a major cause of death and a significant economic burden. In 2016, ∼700,000 Americans aged 65 and over died of AD, and the total health and social care payments for AD in the United States alone exceeded $230 billion (1). Currently, there are no validated disease-modifying therapies that slow the progression of human AD.

Keywords

Alzheimer Disease, Inflammation, Peptide Fragments, Amyloid beta-Peptides

Sponsorship

Wellcome Trust (100140/Z/12/Z)

Wellcome Trust (095317/Z/11/Z)

Identifiers

External DOI: https://doi.org/10.1073/pnas.1715241114

This record's URL: https://www.repository.cam.ac.uk/handle/1810/275412

Rights

Licence:

http://www.rioxx.net/licenses/all-rights-reserved

Statistics

Total file downloads (since January 2020). For more information on metrics see the IRUS guide.